Literature DB >> 9554586

Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid.

A Kruczynski1, F Colpaert, J P Tarayre, P Mouillard, J Fahy, B T Hill.   

Abstract

Vinflunine, or 20',20'-difluoro-3',4'-dihydrovinorelbine, is a novel Vinca alkaloid obtained by hemisynthesis using superacidic chemistry. The most impressive structural modification of this vinorelbine derivative was the selective introduction of two fluorine atoms at the 20' position, a part of the molecule previously inaccessible by classic chemistry. The antitumor activity of vinflunine was evaluated against a range of transplantable murine and human tumors. Vinflunine exhibited marked activity against murine P388 leukemia grafted i.v. when given i.p. in single or multiple doses according to various schedules or in single i.v. or p.o. doses. Increases in life span achieved with vinflunine, as assessed by T/C ratios, ranged from 200% to 457% and proved markedly superior to those of 129-186% obtained with the other Vinca alkaloids tested. Against s.c.-implanted B16 melanoma, multiple i.p. administration of vinflunine proved active in terms of both survival prolongation and tumor growth inhibition, with optimal T/C values and relative areas under the tumor growth curves (rAUC) being 24% and 36%, respectively. The extent of this activity was superior to that noted for vinorelbine under the same experimental conditions. Growth inhibition of human tumor xenografts LX-1 (lung) and MX-1 (breast) was also observed following four weekly i.p. injections of vinflunine as reflected by optimal T/C values of 23% and 26%, respectively, and significant differences in the rAUCs noted for treated versus control animals. It was also noticeable that vinflunine induced considerably more prolonged inhibitory effects on tumor growth than did vinorelbine. These results demonstrate that vinflunine is well tolerated and is definitively active against a range of experimental animal tumor models. Vinflunine activity has been documented in terms of both survival prolongation and tumor growth inhibition, with definite superiority over vinorelbine being shown in each tumor model evaluated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554586     DOI: 10.1007/s002800050764

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

1.  Pharmacokinetics, tissue distribution and excretion of vinflunine.

Authors:  Xiao-Ping Zhao; Xiao-Quan Liu; Yong-Sheng Wang; Huan Wang; Guang-Ji Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

2.  Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials.

Authors:  Jean-Pierre Delord; Jaafar Bennouna; Loïc Mourey; Joël Bougaret; Maud Brandely-Talbot; Pierre Ferré
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

3.  A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.

Authors:  Hanna K Sanoff; Janine M Davies; Christine Walko; William Irvin; Larry Buie; Kimberly Keller; Anastasia Ivanova; Wing-Keung Chiu; Bert H O'Neil; Thomas E Stinchcombe; E Claire Dees
Journal:  Invest New Drugs       Date:  2010-04-13       Impact factor: 3.850

Review 4.  Current chemotherapeutic strategies against bladder cancer.

Authors:  Yozo Mitsui; Hiroaki Yasumoto; Naoko Arichi; Satoshi Honda; Hiroaki Shiina; Mikio Igawa
Journal:  Int Urol Nephrol       Date:  2011-06-12       Impact factor: 2.370

5.  Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.

Authors:  J P Delord; A Ravaud; J Bennouna; P Fumoleau; S Favrel; M C Pinel; P Ferré; F Saliba
Journal:  Invest New Drugs       Date:  2012-09-21       Impact factor: 3.850

Review 6.  Vinflunine.

Authors:  James E Frampton; Marit D Moen
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

7.  How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.

Authors:  Nicolas Isambert; Jean Pierre Delord; Jean Marc Tourani; Pierre Fumoleau; Alain Ravaud; Marie Claire Pinel; Aurelie Petain; Thierry Nguyen; Laurent Nguyen
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

8.  Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.

Authors:  Anna Kruczynski; Isabelle Vandenberghe; Arnaud Pillon; Sabrina Pesnel; Liliane Goetsch; Jean-Marc Barret; Yves Guminski; Alain Le Pape; Thierry Imbert; Christian Bailly; Nicolas Guilbaud
Journal:  Invest New Drugs       Date:  2009-09-24       Impact factor: 3.850

9.  Phase I trial of vinflunine and pemetrexed in refractory solid tumors.

Authors:  Hanna K Sanoff; Janine Davies; Christine Walko; Larry Buie; Wing-Keung Chiu; Anastasia Ivanova; Bert O'Neil; Thomas E Stinchcombe; Kimberly Keller; E Claire Dees
Journal:  Invest New Drugs       Date:  2009-10-15       Impact factor: 3.850

10.  Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development.

Authors:  A Kruczynski; C Etiévant; D Perrin; N Chansard; A Duflos; B T Hill
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.